Equities analysts predict that Genomic Health, Inc. (NASDAQ:GHDX) will announce sales of $111.03 million for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Genomic Health’s earnings, with estimates ranging from $110.00 million to $112.52 million. Genomic Health posted sales of $95.62 million in the same quarter last year, which would indicate a positive year over year growth rate of 16.1%. The company is expected to issue its next earnings report on Thursday, August 1st.
On average, analysts expect that Genomic Health will report full-year sales of $445.67 million for the current financial year, with estimates ranging from $442.00 million to $448.00 million. For the next financial year, analysts expect that the business will report sales of $489.33 million, with estimates ranging from $471.81 million to $504.33 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for Genomic Health.
Genomic Health (NASDAQ:GHDX) last issued its earnings results on Tuesday, May 7th. The medical research company reported $0.34 EPS for the quarter, topping the consensus estimate of $0.29 by $0.05. The company had revenue of $108.80 million for the quarter, compared to the consensus estimate of $106.75 million. Genomic Health had a net margin of 10.35% and a return on equity of 18.70%. The firm’s revenue for the quarter was up 17.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.11) earnings per share.
GHDX opened at $53.13 on Friday. The company has a current ratio of 5.67, a quick ratio of 5.67 and a debt-to-equity ratio of 0.19. The stock has a market cap of $1.93 billion, a price-to-earnings ratio of 50.60 and a beta of 1.05. Genomic Health has a 52-week low of $48.00 and a 52-week high of $92.18.
In related news, CFO G Bradley Cole sold 11,424 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $57.17, for a total value of $653,110.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Bros. Advisors Lp Baker sold 73,735 shares of the stock in a transaction that occurred on Monday, March 11th. The stock was sold at an average price of $74.52, for a total transaction of $5,494,732.20. The disclosure for this sale can be found here. Insiders sold a total of 1,202,954 shares of company stock valued at $84,930,727 over the last three months. 31.30% of the stock is currently owned by insiders.
A number of institutional investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. increased its position in shares of Genomic Health by 166.0% in the first quarter. Northwestern Mutual Wealth Management Co. now owns 790 shares of the medical research company’s stock valued at $55,000 after buying an additional 493 shares in the last quarter. Manchester Capital Management LLC acquired a new position in shares of Genomic Health during the first quarter worth about $56,000. Pearl River Capital LLC acquired a new position in shares of Genomic Health during the first quarter worth about $70,000. C M Bidwell & Associates Ltd. acquired a new position in shares of Genomic Health during the first quarter worth about $83,000. Finally, Royce & Associates LP lifted its stake in shares of Genomic Health by 22.8% during the fourth quarter. Royce & Associates LP now owns 1,473 shares of the medical research company’s stock worth $95,000 after purchasing an additional 273 shares in the last quarter. 95.75% of the stock is owned by institutional investors.
Genomic Health Company Profile
Genomic Health, Inc, a healthcare company, provides clinically actionable genomic information to personalize cancer treatment decisions in the United States and internationally. The company develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, which allows physicians and patients to make individualized treatment decisions.
Featured Article: What is insider trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.